All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Ten days after its JAK1 inhibitor, itacitinib, failed a phase III trial in acute graft-vs.-host-disease (GVHD), Incyte Corp. has finalized a deal that could provide an alternative growth path. It is paying Morphosys AG $750 million up front, investing $150 million in its stock and is on the hook for up to $1.1 billion in milestones for a 50% interest in U.S. rights to the CD19-targeting antibody tafasitamab (MOR-208) and for 100% of the rights in all other territories.
Duluth, Ga.-based Sebacia Inc., which is focused on dermatology and aesthetics, has introduced its new CEO and reported the acquisition of all assets related to Sienna Biopharmaceuticals Inc.'s silver photoparticle technology, which is being reviewed by the FDA for light hair removal.
Eli Lilly and Co.’s acquisition of Dermira Inc. for $1.1 billion in cash enlarges Lilly’s dermatology pipeline with the addition of lebrikizumab, a monoclonal antibody designed to bind IL-13 with high affinity, now in two phase III studies for treating moderate to severe atopic dermatitis (AD) in adolescent and adult patients, ages 12 and older.
California's Amunix Pharmaceuticals Inc. said Roche Holding AG has agreed to license its therapeutic half-life extension technology, XTEN, for an effort to discover and develop new non-oncology therapies. The deal, which includes $40 million up front, plus up to $1.5 billion in development and sales milestones, builds on a previous technology evaluation agreement the companies first inked in 2013.
Fresh off ending one antifibrosis program in December, Boehringer Ingelheim GmbH (BI) is spinning up an expansive new effort in the area this month, promising Singapore-based Enleofen Bio Pte. Ltd. potential payouts of more than $1 billion per product from a preclinical interleukin-11 platform.
Philadelphia-based Aro Biotherapeutics Co. CEO Sue Dillon told BioWorld her firm has “incoming interest from other companies to apply Centyrins to other kinds of drug conjugates,” which could mean more deals with the platform like the one sealed with Ionis Pharmaceuticals Inc.
Nurix Therapeutics Inc. landed its second big pharma collaboration in seven months when it signed with Sanofi SA to discover, develop and commercialize a pipeline of protein degradation therapies. In the Sanofi deal, Nurix receives $55 million up front and is eligible for up to about $2.5 billion in total payments based on achieved milestones. To start, Nurix will design small molecules to induce degradation in three specific targets while Sanofi has the option to up the ante to five targets. Sanofi receives exclusive rights and will handle clinical development and commercialization and Nurix retains the option to co-develop and co-co-promote up to two products in the U.S.
DUBLIN – Shares in Targovax ASA rose as much as 26% Wednesday on news of an option and license agreement in China involving its peptide-based KRAS-directed cancer vaccines, TG-01 and TG-02.
HONG KONG – South Korea’s Ministry of Food and Drug Safety (MFDS) recently granted the first urgent-use licenses to four COVID-19 novel coronavirus diagnostic...
As the COVID-19 outbreak continues to dominate the news, an increasing number of companies have come forward to help. For its part, CHF Solutions Inc., of Eden...
BEIJING – Beijing-based Sihuan Pharmaceutical Holdings Group Ltd. said it has initiated clinical trials of broad-spectrum antiviral favipiravir to treat COVID-19....
Mallinckrodt plc is engaging with the U.S. FDA, NIH and the Biomedical Advanced Research and Development Authority to address the potential use of its INOmax...
HONG KONG – As the number of COVID-19 confirmed cases and deaths continue to rise globally, South Korea’s focus on testing has attracted international attention....
BioWorld Premium
Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.
RSS
